- Home
- WRB vs NTRA Comparison
WRB vs NTRA Comparison
Compare WRB & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRB
- NTRA
- Stock Information
- Founded
- WRB 1967
- NTRA 2003
- Country
- WRB United States
- NTRA United States
- Employees
- WRB N/A
- NTRA N/A
- Industry
- WRB Property-Casualty Insurers
- NTRA Medical Specialities
- Sector
- WRB Finance
- NTRA Health Care
- Exchange
- WRB Nasdaq
- NTRA Nasdaq
- Market Cap
- WRB 27.0B
- NTRA 21.7B
- IPO Year
- WRB N/A
- NTRA 2015
- Fundamental
- Price
- WRB $71.56
- NTRA $168.25
- Analyst Decision
- WRB Hold
- NTRA Strong Buy
- Analyst Count
- WRB 11
- NTRA 16
- Target Price
- WRB $71.18
- NTRA $193.50
- AVG Volume (30 Days)
- WRB 1.7M
- NTRA 1.5M
- Earning Date
- WRB 10-20-2025
- NTRA 08-07-2025
- Dividend Yield
- WRB 2.25%
- NTRA N/A
- EPS Growth
- WRB 15.81
- NTRA N/A
- EPS
- WRB 4.40
- NTRA N/A
- Revenue
- WRB $14,286,154,000.00
- NTRA $1,964,250,000.00
- Revenue This Year
- WRB $9.20
- NTRA $23.93
- Revenue Next Year
- WRB $7.37
- NTRA $15.60
- P/E Ratio
- WRB $16.29
- NTRA N/A
- Revenue Growth
- WRB 11.41
- NTRA 44.38
- 52 Week Low
- WRB $55.80
- NTRA $110.57
- 52 Week High
- WRB $76.38
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- WRB 51.43
- NTRA 64.89
- Support Level
- WRB $70.82
- NTRA $156.71
- Resistance Level
- WRB $71.98
- NTRA $168.33
- Average True Range (ATR)
- WRB 0.91
- NTRA 5.04
- MACD
- WRB 0.03
- NTRA 1.21
- Stochastic Oscillator
- WRB 42.05
- NTRA 98.30
About WRB W.R. Berkley Corporation
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.